BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Monday, January 5, 2026
See today's BioWorld
Home
» Johnson & Johnson targets Actelion and its PAH portfolio for acquisition; shares climb
To read the full story,
subscribe
or
sign in
.
Johnson & Johnson targets Actelion and its PAH portfolio for acquisition; shares climb
Nov. 29, 2016
By
Nuala Moran
LONDON – Europe's largest independent biopharma, Actelion Ltd., is in talks with Johnson & Johnson about a possible acquisition.
BioWorld
